The Tim Ferriss Show

#714: A Glimpse of the Future: Electroceuticals for 70%–90% Remission of Depression, Brain Stimulation for Sports Performance, and De-risking Ibogaine for TBI/PTSD

644 snips
Jan 5, 2024
Nolan Williams, an associate professor at Stanford and director of the Brain Stimulation Lab, discusses groundbreaking advancements in mental health treatment. He explores the promise of electroceuticals and rapid transcranial magnetic stimulation, showcasing their revolutionary effects on treatment-resistant depression. Williams also dives into the therapeutic potential of ibogaine for conditions like PTSD, emphasizing careful clinical approaches. With a focus on personalized care and innovative therapies, he highlights the future of mental health treatment as both hopeful and transformative.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Accelerated TMS Patient Population

  • Accelerated TMS trials focused on patients with treatment-resistant depression, averaging nine years of illness.
  • The severity of depression correlated with the abnormal brain activity sequencing biomarker.
INSIGHT

Accelerated TMS Trial Results

  • Accelerated TMS trials achieved 79% remission in treatment-resistant depression, versus 16% with conventional TMS.
  • Some patients, especially older adults, experience delayed remission up to one month post-treatment.
INSIGHT

Ibogaine for Trauma and Mental Health

  • Ibogaine, derived from an African root bark, shows promise for treating TBI, depression, anxiety, and PTSD.
  • It carries a 1 in 300 risk of death from cardiac arrhythmia but has a high success rate.
Get the Snipd Podcast app to discover more snips from this episode
Get the app